Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 3-Year EPS without NRI Growth Rate is 1.70% as of Jun. 2026, which is 60% below its 10-year median of 4.20. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr48.84. The stock has 2 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 58.66% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Boule Diagnostics AB was 45.90% per year. The lowest was -30.90% per year. And the median was 4.20% per year.
Boule Diagnostics AB (CHIX:BOULs) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Boule Diagnostics AB 3-Year EPS without NRI Growth Rate Related Terms
CHIX:BOULS vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's 3-Year EPS without NRI Growth Rate falls into.
Boule Diagnostics AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 1.70% mean?
Boule Diagnostics AB (CHIX:BOULS) has a 3-Year EPS without NRI Growth Rate of 1.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Boule Diagnostics AB and its competitors. This is 60% below median its historical median of 4.20. According to the industry distribution chart, Boule Diagnostics AB ranks #386 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 58.7%.
Is Boule Diagnostics AB's 3-Year EPS without NRI Growth Rate too high?
Boule Diagnostics AB's current 3-Year EPS without NRI Growth Rate of 1.70% is 60% below median its 10-year median of 4.20. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Boule Diagnostics AB's value of 1.70% is 78.9% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #386 out of 658 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #386 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places Boule Diagnostics AB in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Boule Diagnostics AB's value of 1.70% is 78.9% below this benchmark. While the company's 10-year median is 4.20 vs. the industry median of 8.05, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current 3-Year EPS without NRI Growth Rate of 1.70% is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current 3-Year EPS without NRI Growth Rate is 1.70%, which is 60% below median its own 10-year median of 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current 3-Year EPS without NRI Growth Rate of 1.70%. The stock's GF Value™ is kr48.84, compared to a current price of kr26.30 — trading 46.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 1.70%, which is 60% below median its 10-year median of 4.20 and 78.9% below the Medical Devices & Instruments industry median of 8.05. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current 3-Year EPS without NRI Growth Rate is 1.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.2% below its estimated GF Value™ of kr48.84.
Key valuation signals for CHIX:BOULS:
3-Year EPS without NRI Growth Rate: 1.70% (60% below median its 10-year median of 4.20)
GF Value™: kr48.84 vs. price of kr26.30 (46.2% below fair value)
Industry Position: 78.9% below the Medical Devices & Instruments median (#386 of 658)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
